News in the pharmacotherapy of venous disease

Recently, new knowledge has been gained in the field of both chronic and acute venous disease that has an impact on the care of patients

with these conditions. The incidence of chronic venous disease has been shown to be globally high, in both industrialized and developing

countries. The rate of the most severe cases with an advanced stage of venous failure is approximately twice as high in the population as

has been assumed so far. Among venopharmaceuticals, micronized purified flavonoid fraction remains the agent with the highest degree of

recommendation and is also indicated to pharmacological support of leg ulcer healing, along with pentoxifylline and sulodexide. The care

of patients with venous thromboembolism is laid out in internationally accepted guidelines. In addition to the ACCP Guidelines, a new version

of the IUA Consensus has recently been available that better suits the utilization in clinical practice. Novel anticoagulants represent one

of the therapeutic and preventive options with a limitation in patients with malignant conditions and in pregnancy. Thrombolytic therapy

can be considered in patients with thrombosis in the ileofemoral location. Thromboses of superficial veins longer than 5 cm are indicated to

anticoagulant therapy. Aspirin is accepted in secondary prevention of recurrent venous thrombosis after cessation of anticoagulant therapy

or in the case of a high risk of bleeding, and can be of significance in dual prevention of venous and arterial thrombosis.

Keywords: venous thrombosis, prevention of TED, chronic venous insufficiency, varices, venous ulcers